Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | CA12 | O43570 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | CA4 | P22748 | 5/20 | 0.64 |
| ▸ | CA7 | P43166 | 5/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.64 |
| ▸ | CA6 | P23280 | 4/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | GRK2 | P25098 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363893 | 1.00 | POLB (0.74) | POLBCA12CA1CA2CA4 | |
| SCHEMBL20116457 | 0.89 | POLB (0.78) | POLBCA12CA1CA2CA4 | |
| SCHEMBL3366104 | 0.85 | CA1 (0.67) | POLBCA12CA1CA2CA4 | |
| SCHEMBL3366098 | 0.85 | CA1 (0.67) | POLBCA12CA1CA2CA4 | |
| SCHEMBL26603162 | 0.85 | TSHR (0.78) | POLBCA12CA1CA2CA4 | |
| SCHEMBL26603140 | 0.85 | POLB (0.72) | POLBCA12CA1CA2CA4 | |
| SCHEMBL27542034 | 0.83 | POLB (0.69) | POLBCA12CA1CA2CA4 | |
| SCHEMBL8085608 | 0.82 | TSHR (0.78) | POLBCA12CA1CA2CA4 | |
| SCHEMBL30625999 | 0.82 | POLB (0.68) | POLBCA12CA1CA2CA4 | |
| SCHEMBL12959507 | 0.82 | POLB (0.68) | POLBCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-7122562-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | POLB 90/4885CA12 4878/4885CA1 3797/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | POLB 368/4885CA12 4861/4885CA1 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.